Correlation of in vitro antibody synthesis with the outcome of intravenous γ-globulin treatment of chronic idiopathic thrombocytopenic purpura

J. Bussel, Savita G Pahwa, A. Porges, S. Cunningham-Rundles, B. Koziner, A. Morell, S. Barandun

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Intravenous γ-globulin (IVGG) effectively elevates the platelet count of most patients with chronic idiopathic thrombocytopenic purpura (ITP). This study examined whether this effect was related to changes in in vitro immunoglobulin secretion and suppression in coculture. Before treatment, patient in vitro immunoglobulin secretion was less than 50% of the concurrent control in all eight cases and the patients suppressed antibody synthesis in coculture an average of 39%. After treatment, increases in in vitro immunoglobulin secretion and decreases in suppression were closely related to a good response to IVGG therapy as measured both by acute increases in the platelet count (P<0.05) and by the long-term outcome from therapy (P<0.05). Decreases in platelet-associated IgG correlated with increases in in vitro immunoglobulin secretion (P<0.05). Data consistent with the lack of inhibition of in vitro immunoglobulin secretion following IVGG included long-term increases in both serum IgM and IgG (independent of transfused IgG) and maintenance of the percentage of total IgG that was IgG3. T-cell numbers and subsets and lymphocyte proliferation were unaffected by IVGG. IVGG tends to normalize in vitro immunoglobulin secretion and its suppression in those ITP patients with good clinical responses in conjunction with decreased levels of autoantibody. This evidence suggests that good responders to IVGG may have inhibition of antiplatelet antibody production. IVGG does not appear to interfere with normal antibody production.

Original languageEnglish
Pages (from-to)50-56
Number of pages7
JournalJournal of Clinical Immunology
Volume6
Issue number1
DOIs
StatePublished - Jan 1 1986
Externally publishedYes

Fingerprint

Idiopathic Thrombocytopenic Purpura
Globulins
Immunoglobulins
Immunoglobulin G
Antibodies
Coculture Techniques
Platelet Count
Antibody Formation
Therapeutics
T-Lymphocyte Subsets
Autoantibodies
Immunoglobulin M
In Vitro Techniques
Blood Platelets
Cell Count
Maintenance
Lymphocytes
Serum

Keywords

  • Antibody synthesis
  • idiopathic thrombocytopenic purpura (ITP)
  • intravenous γ-globulin
  • suppression

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Correlation of in vitro antibody synthesis with the outcome of intravenous γ-globulin treatment of chronic idiopathic thrombocytopenic purpura. / Bussel, J.; Pahwa, Savita G; Porges, A.; Cunningham-Rundles, S.; Koziner, B.; Morell, A.; Barandun, S.

In: Journal of Clinical Immunology, Vol. 6, No. 1, 01.01.1986, p. 50-56.

Research output: Contribution to journalArticle

Bussel, J. ; Pahwa, Savita G ; Porges, A. ; Cunningham-Rundles, S. ; Koziner, B. ; Morell, A. ; Barandun, S. / Correlation of in vitro antibody synthesis with the outcome of intravenous γ-globulin treatment of chronic idiopathic thrombocytopenic purpura. In: Journal of Clinical Immunology. 1986 ; Vol. 6, No. 1. pp. 50-56.
@article{7cf65f6271a440e2bd5ca24aaceb1042,
title = "Correlation of in vitro antibody synthesis with the outcome of intravenous γ-globulin treatment of chronic idiopathic thrombocytopenic purpura",
abstract = "Intravenous γ-globulin (IVGG) effectively elevates the platelet count of most patients with chronic idiopathic thrombocytopenic purpura (ITP). This study examined whether this effect was related to changes in in vitro immunoglobulin secretion and suppression in coculture. Before treatment, patient in vitro immunoglobulin secretion was less than 50{\%} of the concurrent control in all eight cases and the patients suppressed antibody synthesis in coculture an average of 39{\%}. After treatment, increases in in vitro immunoglobulin secretion and decreases in suppression were closely related to a good response to IVGG therapy as measured both by acute increases in the platelet count (P<0.05) and by the long-term outcome from therapy (P<0.05). Decreases in platelet-associated IgG correlated with increases in in vitro immunoglobulin secretion (P<0.05). Data consistent with the lack of inhibition of in vitro immunoglobulin secretion following IVGG included long-term increases in both serum IgM and IgG (independent of transfused IgG) and maintenance of the percentage of total IgG that was IgG3. T-cell numbers and subsets and lymphocyte proliferation were unaffected by IVGG. IVGG tends to normalize in vitro immunoglobulin secretion and its suppression in those ITP patients with good clinical responses in conjunction with decreased levels of autoantibody. This evidence suggests that good responders to IVGG may have inhibition of antiplatelet antibody production. IVGG does not appear to interfere with normal antibody production.",
keywords = "Antibody synthesis, idiopathic thrombocytopenic purpura (ITP), intravenous γ-globulin, suppression",
author = "J. Bussel and Pahwa, {Savita G} and A. Porges and S. Cunningham-Rundles and B. Koziner and A. Morell and S. Barandun",
year = "1986",
month = "1",
day = "1",
doi = "10.1007/BF00915364",
language = "English",
volume = "6",
pages = "50--56",
journal = "Journal of Clinical Immunology",
issn = "0271-9142",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Correlation of in vitro antibody synthesis with the outcome of intravenous γ-globulin treatment of chronic idiopathic thrombocytopenic purpura

AU - Bussel, J.

AU - Pahwa, Savita G

AU - Porges, A.

AU - Cunningham-Rundles, S.

AU - Koziner, B.

AU - Morell, A.

AU - Barandun, S.

PY - 1986/1/1

Y1 - 1986/1/1

N2 - Intravenous γ-globulin (IVGG) effectively elevates the platelet count of most patients with chronic idiopathic thrombocytopenic purpura (ITP). This study examined whether this effect was related to changes in in vitro immunoglobulin secretion and suppression in coculture. Before treatment, patient in vitro immunoglobulin secretion was less than 50% of the concurrent control in all eight cases and the patients suppressed antibody synthesis in coculture an average of 39%. After treatment, increases in in vitro immunoglobulin secretion and decreases in suppression were closely related to a good response to IVGG therapy as measured both by acute increases in the platelet count (P<0.05) and by the long-term outcome from therapy (P<0.05). Decreases in platelet-associated IgG correlated with increases in in vitro immunoglobulin secretion (P<0.05). Data consistent with the lack of inhibition of in vitro immunoglobulin secretion following IVGG included long-term increases in both serum IgM and IgG (independent of transfused IgG) and maintenance of the percentage of total IgG that was IgG3. T-cell numbers and subsets and lymphocyte proliferation were unaffected by IVGG. IVGG tends to normalize in vitro immunoglobulin secretion and its suppression in those ITP patients with good clinical responses in conjunction with decreased levels of autoantibody. This evidence suggests that good responders to IVGG may have inhibition of antiplatelet antibody production. IVGG does not appear to interfere with normal antibody production.

AB - Intravenous γ-globulin (IVGG) effectively elevates the platelet count of most patients with chronic idiopathic thrombocytopenic purpura (ITP). This study examined whether this effect was related to changes in in vitro immunoglobulin secretion and suppression in coculture. Before treatment, patient in vitro immunoglobulin secretion was less than 50% of the concurrent control in all eight cases and the patients suppressed antibody synthesis in coculture an average of 39%. After treatment, increases in in vitro immunoglobulin secretion and decreases in suppression were closely related to a good response to IVGG therapy as measured both by acute increases in the platelet count (P<0.05) and by the long-term outcome from therapy (P<0.05). Decreases in platelet-associated IgG correlated with increases in in vitro immunoglobulin secretion (P<0.05). Data consistent with the lack of inhibition of in vitro immunoglobulin secretion following IVGG included long-term increases in both serum IgM and IgG (independent of transfused IgG) and maintenance of the percentage of total IgG that was IgG3. T-cell numbers and subsets and lymphocyte proliferation were unaffected by IVGG. IVGG tends to normalize in vitro immunoglobulin secretion and its suppression in those ITP patients with good clinical responses in conjunction with decreased levels of autoantibody. This evidence suggests that good responders to IVGG may have inhibition of antiplatelet antibody production. IVGG does not appear to interfere with normal antibody production.

KW - Antibody synthesis

KW - idiopathic thrombocytopenic purpura (ITP)

KW - intravenous γ-globulin

KW - suppression

UR - http://www.scopus.com/inward/record.url?scp=0023039645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023039645&partnerID=8YFLogxK

U2 - 10.1007/BF00915364

DO - 10.1007/BF00915364

M3 - Article

VL - 6

SP - 50

EP - 56

JO - Journal of Clinical Immunology

JF - Journal of Clinical Immunology

SN - 0271-9142

IS - 1

ER -